Cytoplasmic HMGB2 orchestrates CALR translocation in the course of immunogenic cell death
Year: 2024
Type: article
Abstract: A recent in vitro study showed that pharmacological inhibition of the nuclear export receptor XPO1 suppresses oxaliplatin-induced nuclear release of HMGB1 and HMGB2, as well as the translocation of CALR to the plasma membrane. Moreover, cell-targeted-HMGB2 protein potently induced CALR exposure, even in the absence of oxaliplatin.
Source: OncoImmunology
Authors: Peng Liu, Liwei Zhao, Oliver Kepp, Guido Kroemer
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,913
Funders: Association pour la Recherche sur le Cancer, Seerave Foundation, Equipex, European Commission, Agence Nationale de la Recherche, Fondation pour la Recherche Médicale, Ligue Contre le Cancer, Centre National de la Recherche Scientifique, Institut Universitaire de France, Institut National Du Cancer, Labex Immuno-Oncology, H2020 European Research Council, HORIZON EUROPE European Research Council
Awards: Next-generation phenotypic screening for oncological applications, Coherent Raman Imaging for the Molecular Study of the OrigiN of diseases, Biomarkers affecting the transition from cardiovascular disease to lung cancer: towards stratified interception., G2786066923, G3423759144, G434337789, G4656594441, Immunogenic cell death (ICD) in the cancer-immune dialogue, G82931992, Université de Paris
OpenAlex ID: W4403794525